AZ-1355
AZ-1355 is an orally active and effctive lipid-lowering agent. AZ-1355 inhibits platelet aggregation in vivo and elevates the prostaglandin I2/thromboxane A2 ratio in vitro[1].
Product Specifications
CAS Number
[75451-07-9]
UNSPSC
12352005
Target
Prostaglandin Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Endocrinology; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/AZ-1355.html
Purity
98.19
Solubility
DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C1=CC=C2OC3=C(OC)C=CC=C3CNC2=C1)OCC
Molecular Formula
C17H17NO4
Molecular Weight
299.32
References & Citations
[1]Wada S, et al. The lipid-lowering profile in rodents. AZ-1355, a new dibenzoxazepine derivative. Atherosclerosis. 1981 Nov-Dec;40 (3-4) :263-71.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
IP; TXA2/TP
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Recombinant Fusobacterium nucleatum subsp.nucleatum Aspartyl/glutamyl-tRNA (Asn/Gln) amidotransferase subunit B (gatB)
Recombinant Fusobacterium nucleatum subsp.nucleatum Aspartyl/glutamyl-tRNA (Asn/Gln) amidotransferase subunit B (gatB)
Recombinant Fusobacterium nucleatum subsp.nucleatum Aspartyl/glutamyl-tRNA (Asn/Gln) amidotransferase subunit B (gatB)
Recombinant Fusobacterium nucleatum subsp.nucleatum Aspartyl/glutamyl-tRNA (Asn/Gln) amidotransferase subunit B (gatB)
Recombinant Fusobacterium nucleatum subsp.nucleatum Aspartyl/glutamyl-tRNA (Asn/Gln) amidotransferase subunit B (gatB)